Table 1.
Current and recently completed phase III trials in gastric and gastroesophageal junction cancer.
| Agent | Clinical trial | Randomization | n | NCT identifier |
|---|---|---|---|---|
| HER2 inhibitors | ||||
| Pertuzumab | JACOB | Pertuzumab in combination with Herceptin and chemotherapy | 780 | NCT01774786 |
| T-DM1 | GATSBY | T-DM1 with or without taxane. | 412 | NCT01641939 |
| Trastuzumab | HELOISE | XP-T (standard versus high-dose) | 400 | NCT01450696 |
|
| ||||
| MET pathway inhibitors | ||||
| Rilotumumab | RILOMET-2 | XP with or without rilotumumab | 450 | NCT02137343 |
| Rilotumumab | RILOMET-1 | ECX with or without rilotumumab | 600 | NCT01697072 |
| Onartuzumab | METGASTRIC | FOLFOX with or without onartuzumab | 800 | NCT01662869 |
|
| ||||
| Cancer stemness inhibitor | ||||
| BBI608 | BRIGHTER | Paclitaxel with or without BBI608 | 680 | NCT02178956 |
|
| ||||
| EGFR inhibitors | ||||
| Panitumumab | REAL-3 | EOX with or without panitumumab | 574 | NCT00824785 |
| Cetuximab | EXPAND | XP with or without cetuximab | 904 | NCT00678535 |
|
| ||||
| Angiogenesis inhibitors | ||||
| Ramucirumab | REGARD | Ramucirumab versus BSC | 355 | NCT00917384 |
| Ramucirumab | RAINBOW | Paclitaxel with or without ramucirumab | 665 | NCT01170663 |
| Regorafenib | INTEGRATE | Regorafenib versus BSC | 150 | Actrn12612000239864 |
T-DM1: trastuzumab emtansine; XP: cisplatin, capecitabine; XP-T: cisplatin, capecitabine; T: trastuzumab; ECX: epirubicin, cisplatin, and capecitabine; FOLFOX: 5FU, folinic acid, and oxaliplatin; EOX: epirubicin, oxaliplatin, and capecitabine; BSC: best supportive care.